CAS 1142090-23-0

GSK2256294A

Description:

GSK2256294A, identified by its CAS number 1142090-23-0, is a chemical compound developed by GlaxoSmithKline, primarily investigated for its potential therapeutic applications. It belongs to a class of compounds known as small molecule inhibitors, specifically targeting certain biological pathways involved in disease processes. The compound exhibits properties that may influence cellular signaling and proliferation, making it a candidate for research in oncology and other therapeutic areas. Its molecular structure includes specific functional groups that contribute to its biological activity and pharmacokinetic profile. As with many investigational drugs, detailed studies on its efficacy, safety, and mechanism of action are essential for understanding its potential use in clinical settings. The compound's characteristics, including solubility, stability, and interaction with biological targets, are critical for its development and eventual application in medical treatments. Further research and clinical trials are necessary to fully elucidate its therapeutic potential and any associated side effects.

Formula: C₂₁H₂₄F₃N₇O

Synonyms:

• GSK2256294A
• Cyclohexanecarboxamide, N-[[4-cyano-2-(trifluoromethyl)phenyl]methyl]-3-[[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino]-, (1R,3S)-
• GSK 2256294A - GSK 2256294
• GSK 2256294;GSK-2256294;GSK2256294;GSK-2256294A;GSK2256294A
• GSK-2256294,GSK-2256294A,GSK2256294A,Inhibitor,Epoxide Hydrolase,GSK2256294,inhibit,cigarette smoke-exposure model,oral,COPD,cardiovascular,inflammation

GSK2256294A

CAS: 1142090-23-0

GSK2256294A

Purity: ≥98%

Molecular weight: 447.46g/mol

Ref: 54-BUP08747

GSK 2256294

Controlled Product

CAS: 1142090-23-0

Formula: C₂₁H₂₄F₃N₇O

Color and Shape: Neat

Molecular weight: 447.457

Ref: TR-G797420

GSK 2256294A

CAS: 1142090-23-0

GSK 2256294A is a diazonium salt that is used to treat bowel diseases. It has been shown to inhibit the production of fatty acid metabolites, such as epoxyeicosatrienoic acids (EETs), and reduce the number of autophagy-positive cells in diabetic patients. This molecule also has cancer-fighting properties and can be used to treat various types of cancers, including colon cancer, breast cancer, and prostate cancer. GSK 2256294A is currently undergoing preclinical studies for treatment of inflammatory bowel disease, cardiovascular disease, and liver disease.

Formula: C₂₁H₂₄F₃N₇O

Purity: Min. 95%

Molecular weight: 447.46 g/mol

Ref: 3D-SVB09023

GSK2256294A

CAS: 1142090-23-0

GSK2256294A (GSK 2256294) is potent, selective inhibitor of recombinant human, rat and mouse sEH with IC50 of 27 pM, 61 pM and 189 pM, respectively.

Formula: C₂₁H₂₄F₃N₇O

Purity: 99.86% - 99.86%

Color and Shape: Solid

Molecular weight: 447.46

Ref: TM-T15430